Pharming « Terug naar discussie overzicht

Radio Pharming !

Jager63
0
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency

Leiden, The Netherlands, February 21, 2023
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants.
45.478 Posts, Pagina: « 1 2 3 4 5 6 ... 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 ... 2270 2271 2272 2273 2274 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 6 mrt 2025 17:38
Koers 0,770
Verschil -0,040 (-4,88%)
Hoog 0,813
Laag 0,768
Volume 19.214.251
Volume gemiddeld 5.681.910
Volume gisteren 8.994.062

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront